Broker's call: Mastek (Buy)

| Updated on June 18, 2020

Anand Rathi

Mastek (Buy)

CMP: ₹370.75

Target: ₹510

Partially consolidated in Q4, Evosys was resilient in the macro environment. It brought $12 million (annualised $80m+) in Q4, reflecting the seasonal pick up and ended FY20 with about 12 per cent growth. The Evosys management tone was positive, expecting 18-20 per cent growth in FY21. Ranked the fourth fastest-growing Indian company in the UK, it is climbing up ranks in Garner’s magic quadrant for Oracle cloud services as well. Margins have fallen to 18-20 per cent (from 22 per cent in FY19), potentially on accelerated investments in the present context.

Mastek ended FY20 positive. Its UK business delivered a second straight quarter of 5 per cent+ growth, almost reverting to Q4 FY19 levels; Evosys integration is on track (first joint win £4 million). Mastek had ₹81.6 crore net cash (after the Evosys-payout) though supported by payables, and may see some reversal ahead. Q4 margins were also the highest after the hiving off, and client-concentration ratios (top-10 now at 51 per cent of revenue, in line with mid-caps) came down. The only negatives were US operations and high receivables — both likely to correct in FY21.

Target retained at ₹510.

Risk: Loss of momentum at Evosys.

Published on June 18, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like